^
Association details:
| Biomarker: | MET amplification + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) + Tepmetko (tepotinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis
Published date:
05/15/2023
Excerpt:
In 19 patients with MET amplification...tepotinib plus gefitinib improved PFS (HR, 0.13; 90% CI, 0.04-0.43) and overall survival (OS; HR, 0.10; 90% CI, 0.02-0.36) versus chemotherapy. Objective response rate was 66.7% with tepotinib plus gefitinib versus 42.9% with chemotherapy; median duration of response was 19.9 months versus 2.8 months....Final analysis of INSIGHT suggests improved PFS and OS with tepotinib plus gefitinib versus chemotherapy in a subgroup of patients with MET-amplified EGFR-mutant NSCLC
DOI:
10.1158/1078-0432.CCR-22-3318
Source:
Title:
364P - Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Published date:
11/28/2022
Excerpt:
Twelve cases of patients with EGFR-mutant METamp NSCLC who received tepotinib plus an EGFR-TKI are presented….Nine patients received tepotinib plus osimertinib, two received tepotinib plus gefitinib, and one received both combinations sequentially....Per the treating physician’s assessment, 11 patients had clinical benefit, eight of whom were considered to have a partial response....The combination of tepotinib plus EGFR-TKIs showed promising clinical activity in patients with METamp NSCLC who have progressed on previous EGFR-TKIs, including those with several lines of prior treatment.
Source:
Title:
MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review
Published date:
03/10/2022
Excerpt:
...a phase Ib/II multicenter randomized trial (INSIGHT) involving EGFR-mutant NSCLC with MET overexpression (immunohistochemistry [IHC] 2+ or 3+) or MET amplification having acquired resistance to EGFR inhibition...survival outcomes were better with tepotinib plus gefitinib than with chemotherapy in patients with MET IHC 3+ (median OS 37.3 vs. 17.9 months; mPFS 8.3 vs. 4.4 months) and in patients with MET amplification (median OS 37.3 vs. 13.1 months; mPFS 16.6 vs. 4.2 months), suggesting improved activity for tepotinib plus gefitinib compared with standard chemotherapy in patients with MET amplification/overexpression (Table 3).
DOI:
10.1007/s40291-021-00568-w
Source:
Title:
Phase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
Excerpt:
TEP+GEF shows promising antitumor activity in pts with MET protein overexpression (IHC3+) and gene amplification EGFR-MT NSCLC and was generally well-tolerated.
DOI:
10.1093/annonc/mdy292
Trial ID:
Source:
Title:
EP08.02-162 - Tepotinib with an EGFR-Tyrosine Kinase Inhibitor (TKI) in Patients with EGFR-mutant MET-amplified NSCLC: A Case Series
Published date:
07/12/2022
Excerpt:
Twelve cases of patients with EGFR-mutant METamp NSCLC, who received tepotinib plus an EGFR-TKI...Ten patients received tepotinib plus osimertinib, one patient received tepotinib plus gefitinib (who also received this combination in the INSIGHT study), and one patient received both combinations sequentially....Eleven patients had clinical benefit per the treating physician’s assessment, of whom eight were considered to have a partial response.
